Lykos Appoints Finance Veteran Scott Giacobello to Board of Directors

Giacobello brings more than 25 years of U.S. and global leadership experience in the biopharmaceutical industry to the role.

Lykos Therapeutics said it has appointed finance veteran Scott Giacobello to the company’s board of directors, effective immediately.

Giacobello, who is the CFO of Aadi Bioscience, brings more than 25 years of U.S. and global leadership experience in the biopharmaceutical industry to the role, according to Lykos.

“We are delighted to welcome Scott to our board,” said Jeff George, chairman of the Lykos board of directors. “He will be an important addition as we grow and build our commercial organization for the potential launch of MDMA-assisted therapy should we receive FDA approval.

“Scott’s extensive financial and operational expertise, deep experience as a public company CFO of multiple biopharma companies, and his leadership roles in both fundraising and building out commercial organizations will be great assets to our board and leadership at Lykos.”

Aadi Bioscience is a commercial-stage, Nasdaq-listed oncology biotech company.

Giacobello previously served as CFO of Nasdaq-listed GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals for $7.2 billion in 2021). At GW, he led the company’s financial strategy, oversaw the build out of the commercial operations for Epidiolex, and helped lead more than $620 million in fundraising.

Prior to GW, he served as CFO for Chase Pharmaceuticals Corp., a clinical-stage CNS biopharmaceutical company, until it was acquired by Allergan in 2016.

Giacobello holds a bachelor’s degree in business administration from the University of Notre Dame and is a certified public accountant.

“This is an exciting time at Lykos as the team prepares for the potential commercialization of what may be the first psychedelic-assisted therapy if MDMA-assisted therapy is approved by the FDA,” Giacobello. “I am grateful for the opportunity to leverage my experience to support the company during this pivotal time as it grows and evolves to bring potential new treatment options to patients.”

With the appointment of Giacobello, the Lykos board will now have nine members, including five who are independent directors.